Evidence
How accurate is GALEAS Bladder?
Results from NHS patients and the manufacturer's validation, with the limits explained.
Results from NHS patients and the manufacturer's validation, with the limits explained.
Source: real-world study of 964 patients referred urgently with blood in the urine across seven NHS urology departments (European Urology Oncology, 2026). Figures apply to that group of patients. See the full evidence.
People referred urgently with blood in the urine gave a urine sample before their planned cystoscopy. Results were compared with cystoscopy and confirmed pathology.
| Measure | Result |
|---|---|
| Bladder cancers in the group | 77 of 964 (8.0%) |
| Cancers detected by GALEAS Bladder | 71 of 77 (92.2%) |
| Muscle-invasive cancers detected | 17 of 17 |
| High-grade cancers detected | 35 of 36 |
| Chance of no cancer after a negative result | 99.3% |
The authors note a limitation: some people tested positive without a tumour visible on cystoscopy, and their later diagnoses were not available.
710 urine samples from three UK clinical cohorts. Specificity was 86% in every category.
Detection is lowest for grade 1 tumours, which grow slowly and are the least likely to spread. NMIBC: non-muscle-invasive. MIBC: muscle-invasive.
GALEAS Bladder was developed by Nonacus with Professor Rik Bryan and Dr Doug Ward at the University of Birmingham, and launched at the European Association of Urology meeting in 2023.
It is UKCA marked under the UK Medical Devices Regulations for triage of people with haematuria. NHS commissioners have since procured at-home GALEAS kits for haematuria pathways, with wider adoption planned across the West Midlands.
Uses such as monitoring after treatment are being researched but are not yet established.
£849 includes your consultation, the test, shipping and follow-up.